keyword
MENU ▼
Read by QxMD icon Read
search

Mucosal leishmaniasis

keyword
https://www.readbyqxmd.com/read/29716641/real-time-pcr-applications-for-diagnosis-of-leishmaniasis
#1
REVIEW
Luca Galluzzi, Marcello Ceccarelli, Aurora Diotallevi, Michele Menotta, Mauro Magnani
Leishmaniasis is a vector-borne disease caused by many Leishmania species, which can infect both humans and other mammals. Leishmaniasis is a complex disease, with heterogeneous clinical manifestations ranging from asymptomatic infections to lesions at cutaneous sites (cutaneous leishmaniasis), mucosal sites (mucocutaneous leishmaniasis) or in visceral organs (visceral leishmaniasis), depending on the species and host characteristics. Often, symptoms are inconclusive and leishmaniasis can be confused with other co-endemic diseases...
May 2, 2018: Parasites & Vectors
https://www.readbyqxmd.com/read/29698432/intraspecies-differences-in-natural-susceptibility-to-amphotericine-b-of-clinical-isolates-of-leishmania-subgenus-viannia
#2
Carlos Franco-Muñoz, Merab Manjarrés-Estremor, Clemencia Ovalle-Bracho
Amphotericin B (AmB) is a recommended medication for the treatment of cutaneous and mucosal leishmaniasis in cases of therapeutic failure with first-line medications; however, little is known about the in vitro susceptibility to AmB of clinical isolates of the subgenus Viannia, which is most prevalent in South America. This work aimed to determine the in vitro susceptibility profiles to AmB of clinical isolates of the species L. (V.) panamensis, L. (V.) guyanensis and L. (V.) braziliensis. In vitro susceptibility to AmB was evaluated for 65 isolates...
2018: PloS One
https://www.readbyqxmd.com/read/29668138/-molecular-typing-of-leishmania-leishmania-amazonensis-and-species-of-the-subgenus-viannia-associated-with-cutaneous-and-mucosal-leishmaniasis-in-colombia-a-concordance-study
#3
Clemencia Ovalle-Bracho, Carolina Camargo, Yira Díaz-Toro, Marcela Parra-Muñoz
INTRODUCTION: Multilocus enzyme electrophoresis (MLEE) is the reference standard for the characterization of Leishmania species. The test is restricted to specialized laboratories due to its technical complexity, cost, and time required to obtain results. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) is used to identify Leishmania species. OBJECTIVE: To establish the concordance between the two tests as identifying methods for circulating species in Colombia...
March 15, 2018: Biomédica: Revista del Instituto Nacional de Salud
https://www.readbyqxmd.com/read/29599090/intranasal-but-not-subcutaneous-vaccination-with-laag-allows-rapid-expansion-of-protective-immunity-against-cutaneous-leishmaniasis
#4
Izabella Pereira Silva Bezerra, Marina Amaral Abib, Bartira Rossi-Bergmann
Mucosal but not parenteral vaccination with whole Leishmania amazonensis promastigotes antigens (LaAg) is known to increase host resistance to infection by an as yet unknown immune mechanism. Since early immune responses are critical for infection establishment, in the present study the differential responses elicited by subcutaneous (s.c.) and intranasal (i.n.) vaccination with LaAg were investigated during the initial stages of infection. For that, BALB/c mice were given two LaAg doses by i.n. or s.c. route prior to L...
March 26, 2018: Vaccine
https://www.readbyqxmd.com/read/29582733/the-elderly-respond-to-antimony-therapy-for-cutaneous-leishmaniasis-similarly-to-young-patients-but-have-severe-adverse-reactions
#5
Alexsandro Souza do Lago, Maurício Nascimento, Augusto M Carvalho, Neuza Lago, Juliana Silva, José Roberto Queiroz, Lucas P Carvalho, Albert Schriefer, Mary Wilson, Paulo Machado, Edgar M Carvalho
There is evidence that elderly patients with cutaneous leishmaniasis (CL) have more mucosal and disseminated diseases than young patients and their cells produce less antigen-induced interferon (IFN)-γ. Herein, we compared the roles of interleukin (IL)-10 and IL-15 as modulators of antigen-induced immune responses and the incidence of adverse reaction and response to therapy in young versus elderly patients with CL. Study participants included 35 senior (60-85 years) and 35 young (18-40 years) patients who had a diagnosis of CL documented by typical cutaneous lesions containing Leishmania braziliensis DNA...
March 26, 2018: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/29550282/liposomal-amphotericin-b-treatment-of-old-world-cutaneous-and-mucosal-leishmaniasis-a-literature-review
#6
REVIEW
Vincent Mosimann, Andreas Neumayr, Daniel H Paris, Johannes Blum
Old World cutaneous and mucosal leishmaniasis is a potentially serious disease. Systemic treatment approaches with pentavalent antimonials, liposomal amphotericin B, fluconazole and miltefosine are increasingly used despite the absence of supportive evidence - to date, no prospective clinical trials have been conducted for systemic treatment of these diseases. We performed a literature search to delineate the contemporary evidence for the use of liposomal amphotericin B, and found that although cure rates of 17/20 (85%) were achieved in immune competent patients with Old World cutaneous leishmaniasis and cure rates of 10/13 (77%) for Old World mucosal leishmaniasis due to L...
June 2018: Acta Tropica
https://www.readbyqxmd.com/read/29543867/toll-like-receptors-2-4-and-9-expressions-over-the-entire-clinical-and-immunopathological-spectrum-of-american-cutaneous-leishmaniasis-due-to-leishmania-v-braziliensis-and-leishmania-l-amazonensis
#7
Marliane Batista Campos, Luciana Vieira do Rêgo Lima, Ana Carolina Stocco de Lima, Thiago Vasconcelos Dos Santos, Patrícia Karla Santos Ramos, Claudia Maria de Castro Gomes, Fernando Tobias Silveira
Leishmania (V.) braziliensis and Leishmania(L.) amazonensis are the most pathogenic agents of American Cutaneous Leishmaniasis in Brazil, causing a wide spectrum of clinical and immunopathological manifestations, including: localized cutaneous leishmaniasis (LCLDTH+/++), borderline disseminated cutaneous leishmaniasis (BDCLDTH±), anergic diffuse cutaneous leishmaniasis (ADCLDTH-), and mucosal leishmaniasis (MLDTH++++). It has recently been demonstrated, however, that while L. (V.) braziliensis shows a clear potential to advance the infection from central LCL (a moderate T-cell hypersensitivity form) towards ML (the highest T-cell hypersensitivity pole), L...
2018: PloS One
https://www.readbyqxmd.com/read/29494584/tegumentary-leishmaniasis-and-coinfections-other-than-hiv
#8
REVIEW
Dalila Y Martínez, Kristien Verdonck, Paul M Kaye, Vanessa Adaui, Katja Polman, Alejandro Llanos-Cuentas, Jean-Claude Dujardin, Marleen Boelaert
BACKGROUND: Tegumentary leishmaniasis (TL) is a disease of skin and/or mucosal tissues caused by Leishmania parasites. TL patients may concurrently carry other pathogens, which may influence the clinical outcome of TL. METHODOLOGY AND PRINCIPAL FINDINGS: This review focuses on the frequency of TL coinfections in human populations, interactions between Leishmania and other pathogens in animal models and human subjects, and implications of TL coinfections for clinical practice...
March 2018: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/29451600/american-tegumentary-leishmaniasis-diagnostic-and-treatment-challenges-in-a-clinical-case
#9
Jully Oyama, Fabiana Borges Padilha Ferreira, Carolina Cella Conter, Daniele Stéfanie Sara Lopes Lera-Nonose, Áquila Carolina Fernandes Herculano Ramos-Milaré, Eneide Aparecida Sabaini Venazzi, Thaís Gomes Verzignassi Silveira, Maria Valdrinez Campana Lonardoni
This clinical case presents a patient with a raised and ulcerative lesion with erythematous edges in the mouth, on the lower lip that was unsuccessfully treated as herpes labialis. Clinical data and laboratory tests (Montenegro skin test, indirect immunofluorescence, direct parasite search and polymerase chain reaction) led to the diagnosis of American tegumentary leishmaniasis caused by Leishmania (Viannia) sp. Treatment with pentavalent antimonial (Glucantime®) for 120 days was not effective and administration of amphotericin B for 30 days resulted in wound healing...
2018: Revista do Instituto de Medicina Tropical de São Paulo
https://www.readbyqxmd.com/read/29411659/safety-and-efficacy-of-miltefosine-monotherapy-and-pentoxifylline-associated-with-pentavalent-antimony-in-treating-mucosal-leishmaniasis
#10
Fernanda Ventin, Carolina Cincurá, Paulo Roberto Lima Machado
Mucosal Leishmaniasis (ML) is a difficult to treat and severe form of Leishmaniasis. In general, more than 40% of subjects with ML have therapeutic failure upon the use of pentavalent antimony (Sbv ) at 20mg/kg/day during 30 days. Additionally, Sbv is a toxic drug that requires parenteral administration, and many patients will need several courses to be cured. In cases that cannot be treated or cured by Sbv , the alternative is amphotericin B, another toxic and parenteral drug. As a consequence, many ML patients will be cured only after years of disease and may present several morbidities due to the aggressiveness of the disease or toxicity related to the treatment...
March 2018: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/29405108/regulatory-t-cell-dynamics-in-cutaneous-and-mucocutaneous-leishmaniasis-due-to-leishmania-braziliensis
#11
Nicolas Barros, Nestor Vasquez, Fernando Woll, Cesar Sanchez, Braulio Valencia, Alejandro Llanos-Cuentas, A Clinton White, Martin Montes
To evaluate the dynamics of regulatory T cells (Tregs) during tegumentary leishmaniasis, we assessed peripheral blood and biopsies from 54 patients. Patients with cutaneous leishmaniasis (CL) had a decreased proportion of Tregs in the peripheral blood, but the proportion was higher in the biopsies of lesions. During treatment of CL, circulating Tregs increased reaching normal proportions, whereas antigen-specific interferon-γ responses diminished. By contrast, circulating Tregs from mucosal leishmaniasis patients failed to normalize during treatment...
March 2018: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/29380732/fulminant-presentation-of-oral-mucosal-leishmaniasis-as-severe-stomatitis-and-periodontitis
#12
M H T de Ruiter, C Stijnis, J W Nolte, A Bart, S L Croonen, J de Lange, M P Grobusch
This case report shows an atypical presentation of mucosal leishmaniasis infantum in the oral cavity resulting in severe stomatitis and periodontitis. The patient was immunocompromised because of rheumatoid arthritis for which he used prednisone and methotrexate. He was treated with intravenous liposomal amphotericin B and recovered within four weeks.
January 2018: Netherlands Journal of Medicine
https://www.readbyqxmd.com/read/29377089/topical-paromomycin-for-treating-solitary-mucosal-leishmaniasis
#13
Riad Kassem, Avi Peretz, Dalit Porat Ben Amy
No abstract text is available yet for this article.
January 29, 2018: International Journal of Dermatology
https://www.readbyqxmd.com/read/29342403/18f-fdg-pet-ct-in-the-follow-up-of-mucosal-leishmaniasis
#14
Raphael A Camargo, Lázaro M Camargo, Marcelo T Sapienza, Carlos A Buchpiguel, Valdir S Amato, Felipe Francisco Tuon
No abstract text is available yet for this article.
January 2018: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/29281707/inhibitory-activity-of-pentacyano-isoniazid-ferrate-ii-iqg-607-against-promastigotes-and-amastigotes-forms-of-leishmania-braziliensis
#15
Camila F Amorim, Luiza Galina, Natália B Carvalho, Nathalia D M Sperotto, Kenia Pissinate, Pablo Machado, Maria M Campos, Luiz A Basso, Valnês S Rodrigues-Junior, Edgar M Carvalho, Diógenes Santiago Santos
M. tuberculosis and parasites of the genus Leishmania present the type II fatty acid biosynthesis system (FASII). The pentacyano(isoniazid)ferrate(II) compound, named IQG-607, inhibits the enzyme 2-trans-enoyl-ACP(CoA) reductase from M. tuberculosis, a key component in the FASII system. Here, we aimed to evaluate the inhibitory activity of IQG-607 against promastigote and amastigote forms of Leishmania (Viannia) braziliensis isolated from patients with different clinical forms of L. braziliensis infection, including cutaneous, mucosal and disseminated leishmaniasis...
2017: PloS One
https://www.readbyqxmd.com/read/29226827/cutaneous-leishmaniasis-in-senegal-a-series-of-38-cases-at-the-aristide-le-dantec-university-hospital-in-dakar
#16
S Diadie, B A Diatta, M Ndiaye, N B Seck, S Diallo, S O Niang, M T Dieng
Our aims were to study the epidemiological, clinical, and parasitological aspects of cutaneous leishmaniasis in the dermatology department of the Aristide Le Dantec hospital. This retrospective study reviewed records of cases treated over a 4-year period (from April 2010 through April 2014) at the HALD Dermatology department. The study included all patients with cutaneous leishmaniasis during the study period. The diagnostic criteria were clinical, parasitological, and histological. The study included 38 patients, corresponding to 9...
December 11, 2017: Médecine et Santé Tropicales
https://www.readbyqxmd.com/read/29211245/low-dose-systemic-or-intralesional-meglumine-antimoniate-treatment-for-american-tegumentary-leishmaniasis-results-in-low-lethality-low-incidence-of-relapse-and-low-late-mucosal-involvement-in-a-referral-centre-in-rio-de-janeiro-brazil-2001-2013
#17
Lucia Regina Brahim, Cláudia Maria Valete-Rosalino, Liliane de Fátima Antônio, Maria Inês Fernandes Pimentel, Marcelo Rosandiski Lyra, Luiz Eduardo de Carvalho Paes, Ananda Dutra da Costa, Iracema Forni Vieira, Cristina Maria Giordano Dias, Maria Cristina de Oliveira Duque, Mauro Celio de Almeida Marzochi, Armando de Oliveira Schubach
BACKGROUND: American tegumentary leishmaniasis (ATL) is a non-lethal parasitic disease that presents with cutaneous (CL) and mucosal (ML) clinical forms. ATL treatment aims at healing the lesions and preventing the development of the late mucosal form. Systemic meglumine antimoniate (MA) therapy with 10-20 mg Sb5+/kg/day is the first choice of treatment. However, alternative therapies using 5 mg Sb5+/kg/day or intralesional (IL) MA are the usual regimens at the National Institute of Infectious Diseases (NIID), Rio de Janeiro, Brazil...
December 2017: Memórias do Instituto Oswaldo Cruz
https://www.readbyqxmd.com/read/29197952/first-identification-of-l-major-in-a-dog-in-an-endemic-area-of-human-cutaneous-leishmaniasis-in-iraq-molecular-and-phylogenetic-studies
#18
Mariwan M M Al-Bajalan, Sherko S Niranji, Sirwan M A Al-Jaf, Hirotomo Kato
Canine leishmaniasis (CanL) caused by Leishmania infantum (L. infantum) is considered as a zoonotic disease and within the last few decades, studies have identified the parasite as a major causative agent of human visceral leishmaniasis. However, in dogs, few recent studies have determined L. major as a cause of cutaneous manifestations and L. tropica as an etiological agent for cutaneous lesions involving mucosa. Interestingly, current study has found canine cutaneous lesions with mucosal involvement in a dog diagnosed with L...
February 2018: Parasitology Research
https://www.readbyqxmd.com/read/29187956/-leg-ulcer-revealing-cutaneous-leishmaniasis
#19
Elalouani Elmehdi, Bachar Zerkly
Leishmaniases are parasitic diseases occurring in endemic tropical and subtropical areas and caused by protozoa of the genus leishmania, transmitted by a diptera (sand fly). We here report a case of topical cutaneous leishmaniasis discovered in a 15-year old boy with painless ulcer on his left leg, who had been staying in South Africa. Clinical examination showed painless non-itchy ulcer, occurred 1 month before, on the antero-internal part of his left leg with crusts and scars caused by insect bites, all evolving in a context of patient's general health status, without mucosal or visceral lesions...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/29167671/immune-checkpoint-targets-for-host-directed-therapy-to-prevent-and-treat-leishmaniasis
#20
REVIEW
Rajiv Kumar, Shashi Bhushan Chauhan, Susanna S Ng, Shyam Sundar, Christian R Engwerda
Leishmaniasis encompasses a group of diseases caused by protozoan parasites belonging to the genus Leishmania . These diseases range from life threatening visceral forms to self-healing cutaneous lesions, and each disease manifestations can progress to complications involving dissemination of parasites to skin or mucosal tissue. A feature of leishmaniasis is the key role host immune responses play in disease outcome. T cells are critical for controlling parasite growth. However, they can also contribute to disease onset and progression...
2017: Frontiers in Immunology
keyword
keyword
50609
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"